Atsena Therapeutics announced in a press release that the FDA granted its gene therapy product candidate, ATSN-201, the regenerative medicine advanced therapy (RMAT) designation to treat X-linked ...

As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission. Prevent Blindness has promoted five leaders to further its efforts and ...